Nomograms on salvage radiotherapy

Nomograms on salvage radiotherapy

Cleveland Clinic

2 months
3 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Shauna Campbell, MD of Cleveland Clinic shares three nomograms that were presented on salvage radiotherapy.

_____

The integration of prostate-specific antigen (PSA) kinetics into a nomogram widely used to predict outcomes of salvage therapy offers physicians and patients a more nuanced, longer-term look at prostate cancer-specific outcomes.

In 2007, a multi-institutional cohort led by Cleveland Clinic’s Glickman Urological and Kidney Institute developed a nomogram to predict prostate cancer-specific and all-cause mortality at six years after salvage radiotherapy (SRT).

Almost a decade later, a study led by Cleveland Clinic Cancer Center radiation oncologist Rahul D. Tendulkar, MD, updated the nomogram with evidence that early initiation of SRT following radical prostatectomy (RP) reduced biochemical failure (BF) and distant metastases (DM).

The researchers’ most recent update to the nomogram was presented at the 2019 annual meeting of the American Society for Radiation Oncology (ASTRO).

“One critique of our previous update was the lack of PSA kinetics among the predictive factors,” says Shauna Campbell, DO, chief resident, radiation oncology, Cleveland Clinic. “This version of the nomogram adds initial postoperative PSA level and PSA doubling time [PSADT] to the picture.”

Read the rest here: https://consultqd.clevelandclinic.org/postprostatectomy-prostate-specific-antigen-kinetics-associated-with-recurrence-after-salvage-radiation/

Up Next Autoplay
Lymphopenia: How This Affects Clinicians and Treatment Today @CleClinicNews
Lymphopenia: How This Affects Clinicians and Treatment Today @CleClinicNews
Category: Non-Hodgkin Lymphoma
3 Views
Cancer-News 22 hours
HORIZON Study #ASH19 @RushMedical
HORIZON Study #ASH19 @RushMedical
Category: Multiple Myeloma
0 Views
ash 22 hours
Immune Status, Inflammation Can Predict Mortality @CleClinicNews @CleClinicMD
Immune Status, Inflammation Can Predict Mortality @CleClinicNews @CleClinicMD
Category: Non-Hodgkin Lymphoma
0 Views
Cancer-News 23 hours
Phase I Study of Duvelisib in CLL/SLL #ASH19 #ASH @DanaFarber
Phase I Study of Duvelisib in CLL/SLL #ASH19 #ASH @DanaFarber
Category: Chronic Lymphocytic Leukemia
11 Views
ash 1 day
MANIFEST, a Phase 2 Study of CPI-0610 @MountSinaiNYC #ASH #ASH19
MANIFEST, a Phase 2 Study of CPI-0610 @MountSinaiNYC #ASH #ASH19
Category: Other
0 Views
ash 1 day
Phase I Study Evaluating NKTR-255 in MM and NHL #ASH #ASH19 @DanaFarber
Phase I Study Evaluating NKTR-255 in MM and NHL #ASH #ASH19 @DanaFarber
Category: Multiple Myeloma
0 Views
ash 2 days
Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of  Hematology (ASH) 2019 Annual Meeting
Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of Hematology (ASH) 2019 Annual Meeting
Category: Immunotherapy
2 Views
cancernewsupdate 2 days
New PreClinical Data for its IL-15 Agonist, NKTR-255 #ASH19 #ASH
New PreClinical Data for its IL-15 Agonist, NKTR-255 #ASH19 #ASH
Category: Immunotherapy
1 Views
ash 2 days
Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Category: Breast Cancer
2 Views
cancernewsupdate 2 days
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL: How This Affects Clinicians? #ASH19 #ASH
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL: How This Affects Clinicians? #ASH19 #ASH
Category: Chronic Lymphocytic Leukemia
0 Views
ash 2 days